Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| John Campbell Robertson | M | 73 |
University of Cambridge
| 30 years |
| Dame Dowling | M | 71 |
University of Cambridge
| 31 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jonathan Aberman | M | - |
University of Cambridge
| 8 years |
| Lisa M. Kreiling | M | - |
University of Cambridge
| 5 years |
| Ting Min Tan | F | 55 |
University of Cambridge
| 7 years |
| Simon Holden | M | 48 |
University of Cambridge
| 5 years |
| Jason Wulfsohn | M | 52 |
University of Cambridge
| 4 years |
| Xiao Hong Xi | M | 61 |
University of Cambridge
| 7 years |
| Tatjana Anni Hilde May | F | 58 |
Shire Plc /Old/
 Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | 7 years |
| Sofia Maroudia | F | 47 |
University of Cambridge
| 7 years |
| Iain Kilty | M | - |
University of Cambridge
| 4 years |
| Andrew O'Neill | M | - |
University of Cambridge
| 3 years |
| Regina Ekström | F | 61 |
Mars UK Ltd.
 Mars UK Ltd. Food: Specialty/CandyConsumer Non-Durables Part of Mars, Inc., Mars UK Ltd. is a company that manufactures chocolate, confectionery and pet food. The company is based in London, UK. | 8 years |
| Jonathan Morgan | M | - |
University of Cambridge
| 4 years |
| Ernesto Schmitt | M | 53 |
University of Cambridge
| 4 years |
| Herman Grutter | M | - |
University of Cambridge
| 3 years |
| Chris Spira | M | - |
University of Cambridge
| 3 years |
| Shane N. O. Williams | M | - |
University of Cambridge
| 3 years |
| Marek Nowosielski | M | - |
University of Cambridge
| 4 years |
| Hania Mohammed Ayesh Al-Sabaawi | F | 53 |
University of Cambridge
| 4 years |
| Owen Wilson | M | 48 |
University of Cambridge
| 3 years |
| James Titmuss | M | 49 |
University of Cambridge
| 3 years |
| Chirstopher David Kingsman | M | 49 |
University of Cambridge
| 4 years |
| Gi-Jeong Han | M | 60 |
University of Cambridge
| 3 years |
| Jonathan Kolodny | M | 55 |
University of Cambridge
| 3 years |
| Wilfred E. Booij | M | - |
University of Cambridge
| 3 years |
| Sam Barnett | M | - |
University of Cambridge
| 4 years |
| Claudio Corbetta | M | 51 |
University of Cambridge
| 4 years |
| John Eric Francia | M | 51 |
University of Cambridge
| 1 years |
| John Downing | M | 52 |
University of Cambridge
| 4 years |
| Anita Graham | F | 52 |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | 4 years |
| Jaroslava Korpanec | M | - |
University of Cambridge
| 3 years |
| Paul Sheppard | M | - |
University of Cambridge
| 3 years |
| Johan bin Mahmood, | - | - |
University of Cambridge
| 4 years |
| Brendan Ludden | M | - |
University of Cambridge
| 4 years |
| James Marshall | M | 57 |
University of Cambridge
| 1 years |
| Jon Kirk | M | - |
University of Cambridge
| 3 years |
| Damien Coady | M | - |
University of Cambridge
| 3 years |
| Siu Chun Hung | M | 56 |
University of Cambridge
| 4 years |
| Ashish Chandarana | M | - |
University of Cambridge
| 1 years |
| Marc Cohen | M | - |
University of Cambridge
| 3 years |
| Simon Peacock | M | - |
University of Cambridge
| 4 years |
| Hung I Chin | M | 56 |
University of Cambridge
| 1 years |
| Trent Eddy | M | - |
University of Cambridge
| 3 years |
| Dave Sharma | M | - |
University of Cambridge
| 3 years |
| Steve Damment | M | - |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | 13 years |
| Twalha Dhunnoo | M | - |
University of Cambridge
| 4 years |
| Wang Wai Ng | M | 61 |
University of Cambridge
| 2 years |
| Chun Peng Wong | M | 57 |
University of Cambridge
| 1 years |
| Mark Volanthen | M | - |
University of Cambridge
| 3 years |
| Shen Yi Thio | M | 57 |
University of Cambridge
| 1 years |
| David Odgers | M | - |
University of Cambridge
| 3 years |
| Wai Han Lock | M | 57 |
University of Cambridge
| 1 years |
| Robert Swerling | M | - |
University of Cambridge
| 1 years |
| Alister James Hart | M | - |
University of Cambridge
| 4 years |
| Georg Müller | M | 61 |
University of Cambridge
| 1 years |
| Llewellyn Richard Dodds John | M | 48 |
University of Cambridge
| 4 years |
| Scott Martin | M | - |
University of Cambridge
| 4 years |
| Kathleen Anne Nealon | F | 70 |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | 4 years |
| Alex Kuropatwa | M | - |
University of Cambridge
| 4 years |
| Craig S. Majernik | M | - |
University of Cambridge
| 1 years |
| Alex Lloyd | M | - |
University of Cambridge
| 1 years |
| Barbara H. Deptula | F | 69 |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | 4 years |
| Eliseo Salinas | M | 69 |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | 4 years |
| Chih Chiang Fan | M | - |
University of Cambridge
| 3 years |
| Mohamed Azmi bin Mohamed Lila | M | 60 |
University of Cambridge
| 3 years |
| Christina Drews | F | - |
University of Cambridge
| 3 years |
| Martin Murphy | M | 55 |
University of Cambridge
| 3 years |
| Clive Thomson | M | 58 |
University of Cambridge
| 1 years |
| Avnish Mehra | M | - |
University of Cambridge
| 2 years |
| Karen Guch | F | - |
University of Cambridge
| 3 years |
| David Pickering | M | - |
University of Cambridge
| 1 years |
| Michael Cola | M | 64 |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | 5 years |
| Emil A. Gjester | M | - |
University of Cambridge
| 2 years |
| Patrick J. Langlois | M | 78 |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | 3 years |
| Melissa Geraldine Earlam | F | - |
University of Cambridge
| 3 years |
| Malcolm Baker | M | 54 |
University of Cambridge
| 1 years |
| Tze Chang Lai | M | 56 |
University of Cambridge
| 3 years |
| Timothy Cooney | M | 58 |
University of Cambridge
| 2 years |
| Sifelani Thapelo | M | 59 |
University of Cambridge
| 3 years |
| Matthew Emmens | M | 72 |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | 5 years |
| Géraldine Matchett | F | 52 |
University of Cambridge
| 1 years |
| Shahril Ridza bin Ridzuan | M | 54 |
University of Cambridge
| 1 years |
| Debashish Bhattacharjee | M | 59 |
University of Cambridge
| 3 years |
| Benjamin James Lee | M | 52 |
University of Cambridge
| 4 years |
| Helmut Becker | M | 55 |
University of Cambridge
| 3 years |
| Ian Narev | M | 56 |
University of Cambridge
| 3 years |
| Xiao Feng Liu | M | 61 |
University of Cambridge
| 3 years |
| Richard Chapman | M | 53 |
University of Cambridge
| 4 years |
| Jonathan Michael Poole | M | 49 |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | 8 years |
| Chris Hollowood | M | 50 |
University of Cambridge
| 3 years |
| Shay Ramalingam | M | 48 |
University of Cambridge
| 3 years |
| David E. Mosedale | M | - |
University of Cambridge
| 3 years |
| Jonathan Hepple | M | 53 |
University of Cambridge
| 4 years |
| Lau Yui Chan | M | 57 |
University of Cambridge
| 1 years |
| Barney Pell | M | - |
University of Cambridge
| 4 years |
| Michael Borrell | M | 62 |
University of Cambridge
| 1 years |
| Nicholas James Clarry | M | 52 |
University of Cambridge
| 4 years |
| Wei Liu | M | 67 |
University of Cambridge
| 3 years |
| Gidofalvy Z. Elemer | M | - |
University of Cambridge
| - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Andrew David Wells
- Personal Network
